K Number
K091795
Device Name
MEDTRADE PRODUCTS CELOX TRAUMA GAUZE
Date Cleared
2009-11-20

(156 days)

Product Code
Regulation Number
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
CELOX Trauma Gauze is intended to be available Over The Counter for the following indication. Indications For OTC (Over The Counter) Use: CELOX Trauma Gauze is indicated for temporary external use to control bleeding of lacerations, minor cuts and abrasions. CELOX Trauma Gauze is indicated for temporary external use to control moderate to severe bleeding.
Device Description
CELOX Trauma Gauze Rx & OTC is identical in composition to Aquanova Super Absorbent Dressing Rx & OTC cleared in K070175 on July 25, 2007
More Information

No
The summary describes a hemostatic gauze and does not mention any computational or analytical capabilities that would suggest the use of AI or ML.

Yes
The device is intended to control bleeding, which is a therapeutic function.

No
The device, CELOX Trauma Gauze, is indicated for controlling bleeding from injuries, not for diagnosing medical conditions.

No

The device is a physical gauze product intended to control bleeding, not a software application.

Based on the provided text, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is to control bleeding of lacerations, minor cuts, abrasions, and moderate to severe bleeding. This is a direct therapeutic action on the body, not a diagnostic test performed on samples taken from the body.
  • Device Description: The device is described as a gauze, which is a physical material used for wound care.
  • Lack of IVD Characteristics: There is no mention of analyzing samples (like blood, urine, etc.), detecting biomarkers, or providing diagnostic information.

IVD devices are used to examine specimens from the human body to provide information for diagnosis, monitoring, or screening. This device's function is to physically stop bleeding, which is a treatment, not a diagnostic process.

N/A

Intended Use / Indications for Use

CELOX Trauma Gauze is intended to be available Over The Counter for the following indication.

Indications For OTC (Over The Counter) Use:

CELOX Trauma Gauze is indicated for temporary external use to control bleeding of lacerations, minor cuts and abrasions.

CELOX Trauma Gauze is indicated for temporary external use to control moderate to severe bleeding.

Product codes (comma separated list FDA assigned to the subject device)

QSY, FRO

Device Description

CELOX Trauma Gauze Rx & OTC is identical in composition to Aquanova Super Absorbent Dressing Rx & OTC cleared in K070175 on July 25, 2007 for:

(Rx) Under the supervision of a healthcare professional AQUANOVA may be used for wounds such as leg ulcers (Stages I-IV), diabetic ulcers, surgical wounds (post-operative, donor sites, dermatological), burns (first and second degree), and the management of surgical or traumatic wounds which have been left to heal by secondary intention.

AQUANOVA may also be used for the local management of wounds that are prone to bleeding such as wounds that have been surgically or mechanically debrided, donor sites, and traumatic wounds. AQUANOVA can be used in the control of minor bleeding.

Additionally, AQUANOVA may be used for exudate absorption in oncology wounds (e.g. fungating cutaneous tumours, cutaneous metastases and Kaposi's sarcomas).

(OTC) MedTrade Products AQUANOVA Super-Absorbent OTC is indicated for minor burns, superficial cuts, lacerations and abrasions, and minor irritations of the skin.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

In vivo testing evaluated the efficacy of CELOX Trauma Gauze to provide hemostasis in femoral artery wound model. This data supports the effectiveness of the CELOX Trauma Gauze in achieving hemostasis in a femoral artery wound model.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K080097, K090026

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

K070175

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

N/A

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

July 28, 2023

MedTrade Products Ltd. c/o Jonathan Ranfield Director, Quality Assurance & Regulatory Affairs Electra House, Crewe Business Park Crewe, Cheshire, CW1 6GL United Kingdom

Re: K091795 Trade/Device Name: MedTrade Products CELOX Trauma Gauze OTC Regulatory Class: Unclassified Product Code: QSY

Dear Jonathan Ranfield:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated November 20, 2009. Specifically, FDA is updating this SE Letter because FDA has better categorized your device technology under product code OSY.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Julie Morabito, OHT4: Office of Surgical and Infection Control Devices, 240-402-3839, Julie.Morabito@fda.hhs.gov.

Image /page/0/Picture/7 description: The image shows the signature of Julie A. Morabito. The text "Sincerely," is written above the signature. The signature is followed by "-S", which likely indicates that it is a signed document. The signature is in a clear, legible font.

Julie Morabito, Ph.D. Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

1

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized graphic of an abstract eagle or bird-like figure, with three curved lines representing its wings or body.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-O66-0609 Silver Spring, MD 20993-0002

MedTrade Products Ltd. % Mr. Jonathan Ranfield Director, QA and RA Electra House, Crewe Business Park Crewe, Cheshire, CW1 6GI, United Kingdom

Re: K091795

Trade/Device Name: MedTrade Products CELOX Trauma Gauze OTC Regulation Number: Unclassified Regulation Name: NA Regulatory Class: Unclassified Product Code: FRO Dated: October 29, 2009 Received: November 2, 2009

Dear Mr. Ranfield:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

NOV 20 2009

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

2

Page 2 - Mr. Jonathan Ranfield

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Mark McMullen

Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

3

K071795

Indications for Use

510(k) Ko91795

Device Name: MedTrade Products CELOX Trauma Gauze OTC

CELOX Trauma Gauze is intended to be available Over The Counter for the following indication.

Indications For OTC (Over The Counter) Use:

CELOX Trauma Gauze is indicated for temporary external use to control bleeding of lacerations, minor cuts and abrasions.

Mark N. Millenson

(Division Sign-Oft) (Division Sign-Off)
Division of Surgical, Orthopedic,
Division of Surgices Division of Surg.
and Restorative Devices

510(k) Number -

Prescription Use AND/OR Over-The-Counter Use (Per 21 CFR 801 Subpart D) (21 CFR 801 Subpart C) .

(PLEASE DO NOT WRITE BELOW THIS LINE, CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

4

Page 1 of 1

Indications for Use

510(k) : ''' ' K091795

Device Name: MedTrade Products CELOX Trauma Gauze

Indications For Prescription Use:

CELOX Trauma Gauze is indicated for temporary external use to control moderate to severe bleeding.

Prescription Use (Per 21 CFR 801 Subpart D)

AND/OR Over-The-Counter Use_ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE, CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Daniel Krame for MXM

(Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number K091795

5

091795

page 1 of 2 Medtrade

2. 510(k) SUMMARY

Sponsor

MedTrade Products Limited Electra House Crewe Business Park Crewe Cheshire CW1 6GL വി

NOV 2 0 2009

Telephone: +44 1270 500019

Fax: +44 1270 500045

Registration Number: 9614493

Contact Person: Jonathan Ranfield

Date Summary was Prepared

June 12, 2009.

Device Information

Proprietary Name:

CELOX Trauma Gauze

CELOX Trauma Gauze OTC

Trauma Gauze Common Name:

Classification Name: Dressing, Unclassified

Predicate Device

MedTrade Products Limited: CELOX Hemostatic Granules On Sheet (K080097)

HemCon: ChitoGauze (K090026)

Device Description

CELOX Trauma Gauze Rx & OTC is identical in composition to Aquanova Super Absorbent Dressing Rx & OTC cleared in K070175 on July 25, 2007 for:

(Rx) Under the supervision of a healthcare professional AQUANOVA may be used for wounds such as leg ulcers (Stages I-IV), diabetic ulcers, surgical wounds (post-operative, donor sites, dermatological), burns (first and second degree), and the management of surgical or traumatic wounds which have been left to heal by secondary intention.

AQUANOVA may also be used for the local management of wounds that are prone to bleeding such as wounds that have been surgically or mechanically debrided, donor sites, and traumatic wounds. AQUANOVA can be used in the control of minor bleeding.

Additionally, AQUANOVA may be used for exudate absorption in oncology wounds (e.g. fungating cutaneous tumours, cutaneous metastases and Kaposi's sarcomas).

(OTC) MedTrade Products AQUANOVA Super-Absorbent OTC is indicated for minor burns, superficial cuts, lacerations and abrasions, and minor irritations of the skin.

Medtrade Products Ltd Medical Conne Bas ness back Linese Chester Chestill

Image /page/5/Picture/28 description: The image shows a blurry, low-resolution image of what appears to be a person's face. The details are not clear due to the image quality. The person seems to be wearing a dark-colored shirt or jacket.

" = = = (t) 1270 5000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000

op one Me Me Beach Tegan Section of the Hunts Course Begineer Burn Line Street Charact

6

K091795

K091795
page 2 of 2

In vivo testing evaluated the efficacy of CELOX Trauma Gauze to provide hemostasis in femoral artery wound model. This data supports the effectiveness of the CELOX Trauma Gauze in achieving hemostasis in a femoral artery wound model. In addition the CELOX Trauma Gauze is substantially equivalent to other legally marketed chilosan based bandages with the same indications. With this 510(k) MedTrade is proposing to add the following indications to CELOX Trauma Gauze Rx and Celox Trauma Gauze OTC

CELOX Trauma Gauze Rx is indicated for temporary external use to control moderate to severe bleeding.

CELOX Trauma Gauze OTC is indicated for temporary external use to control bleeding of lacerations, minor cuts, and abrasions.

The predicate devices are indicated Rx for temporary external use to control moderate to severely bleeding wounds and OTC for temporary external use to control stop bleeding from minor wounds, minor cuts and minor abrasions. The CELOX Trauma Gauze is substantially equivalent to these predicate devices in that it has similar intended use and indications to the chitosan based predicate devices. The predicate devices are MedTrade Products Limited CELOX Hemostatic Granules On Sheet (K080097), cleared July 8, 2008 and HemCon: ChitoGauze (K090026), cleared March 31, 2009.

Indications for use

CELOX Trauma Gauze Rx is indicated for temporary external use to control moderate to severe bleeding.

CELOX Trauma Gauze OTC is indicated for temporary external use to control bleeding of lacerations, minor cuts, and abrasions.